Klowden Michael 4
4 · NKGen Biotech, Inc. · Filed Feb 14, 2024
Insider Transaction Report
Form 4
Klowden Michael
Director
Transactions
- Award
Stock Option (right to buy)
2024-02-12+300,000→ 300,000 totalExercise: $1.62→ Common Stock (300,000 underlying)
Footnotes (1)
- [F1]On February 12, 2024, the reporting person was granted 300,000 options pursuant to the Company's 2023 Equity Incentive Plan, vesting in equal installments on the first of each month, beginning October 1, 2023, and ending October 1, 2026, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.